Daily Migraine Medication and NSAIDs Linked to Stroke in Young Adult

A 28-year-old woman's sudden loss of speech and right-side weakness has prompted neurologists to examine the potential stroke risks of common migraine treatments. The patient had been taking sumatriptan daily for three years to manage chronic migraines, while also using the NSAID diclofenac intermittently for pain control. Her case represents a concerning pattern that may be more widespread than previously recognized.

The case highlights a concerning combination: sumatriptan works by constricting blood vessels to relieve migraine pain, while NSAIDs can affect blood clotting and vessel function. Together, these medications may create conditions that increase stroke risk, particularly when used chronically. The patient also had minor metabolic issues including subclinical hypothyroidism and borderline high cholesterol, which may have compounded the medication effects.

Stroke in adults under 50 is relatively rare, affecting roughly 15 people per 100,000 annually—about the same odds as being struck by lightning twice in a lifetime. However, when it does occur in young adults, it often happens without traditional risk factors like heart disease or diabetes. This makes identification of medication-related causes crucial for both treatment and prevention of future episodes.

The diagnostic process revealed important lessons about imaging technology in stroke detection. While emergency departments typically rely on CT scans for rapid stroke diagnosis, this case required the more sensitive 1.5-Tesla MRI to identify the tiny brain lesions. The punctate lesions in the M4 cortical territory were so small they would have been invisible on standard CT imaging, potentially leading to a missed diagnosis.

The patient had experienced a brief neurological episode three years earlier, though brain imaging at that time showed no abnormalities. This earlier event, combined with her recent stroke, suggests that chronic medication use may have gradually increased her vascular risk over time. The pattern raises questions about whether current migraine treatment protocols adequately account for cumulative vascular effects.

This case report adds to growing evidence that clinicians should maintain heightened awareness when treating young migraine patients who develop sudden neurological symptoms. The combination of vasoconstrictive migraine medications with anti-inflammatory drugs may represent an underrecognized risk factor that requires more careful monitoring and potentially modified treatment approaches in chronic migraine management.